EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL






Immunology Letters 149(1-2): 30-40

Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL

Recombinant immunotoxins consisting of small antibody fragments fused to cytotoxic moieties are being evaluated for use in prospective antibody-targeted cancer therapies. A receptor tyrosine kinase known as c-Met is overexpressed in a vast range of human malignancies, making it an ideal target for antibody-mediated delivery of numerous cytotoxic agents. A single Fab molecule capable of binding to human c-Met with high affinity and specificity was previously identified using antibody phage-display technology. In order to develop a molecule to increase both the cytotoxicity and anti-tumor activity of the anti-c-Met molecule, a recombinant immunotoxin anti-c-Met/PE38KDEL was constructed and expressed by fusing the human anti-c-Met single-chain variable fragment (ScFv) with a modified Pseudomonas exotoxin A (PE38KDEL). Purified anti-c-Met/PE38KDEL was demonstrated to specifically bind to cells of c-Met-positive human hepatoma cell lines, causing a proliferation defect by inducing caspase-3/8-mediated apoptosis, as observed by in vitro assays. Furthermore, anti-c-Met/PE38KDEL administration was shown to inhibit the growth of hepatocellular carcinoma xenografts in vivo through suppression of Ki-67 expression and enhancement of tumor cell apoptosis rates. Cumulatively, the current findings demonstrate the successful construction of a recombinant immunotoxin capable of accurately targeting c-Met-positive human hepatoma cell lines both in vitro and in vivo, providing a novel compound with potential for applications as an alternative therapy for c-Met-positive cancer management. A recombinant immunotoxin, anti-c-Met/PE38KDEL, was constructed. This immunotoxin can inhibit the proliferation of human hepatoma cell line. This immunotoxin can inhibit the growth of hepatocellular carcinoma xenograft.


Accession: 036599480

PMID: 23026237

DOI: 10.1016/j.imlet.2012.09.006



Related references

Bailon, P.; Spence, C.; Schaffer, C.A.n; Kreitman, R.J.; Pastan, I., 1993: Single chain immunotoxin anti-TAC -PE38KDEL that is targeted to kill IL-2R bearing cells. Journal of Molecular Recognition 6(1): 12

Francisco, J.A.; Gawlak, S.L.; Siegall, C.B., 1997: Construction, expression, and characterization of BD1-G28-5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1. The major limitation to the use of immunotoxins in the clinic is the toxicity associated with the toxin moiety. BD1-G28-5 single-chain Fv (sFv) is a single-chain immunotoxin targeted to human CD40 and consists of bryodin 1 (BD1), a plant ribosome-...

Wang, H.; Dai, J.; Li, B.; Fan, K.; Peng, L.; Zhang, D.; Cao, Z.; Qian, W.; Wang, H.; Zhao, J.; Guo, Y., 2007: Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A. Vascular leak syndrome (VLS) is the major dose-limiting toxicity of immunotoxin therapy. In our previous study, a modified PE38KDEL, denoted PE38KDELKQK, was engineered to eliminate VLS. The PE38KDELKQK-based immunotoxin has been proved to retain...

Ma, S.; Hu, H.; Thompson, J.; Stavrou, S.; Scharff, J.; Neville, D.M., 1997: Genetic construction and characterization of an anti-monkey CD3 single-chain immunotoxin with a truncated diphtheria toxin. We have previously developed a chemically conjugated anti-rhesus monkey CD3 immunotoxin FN18-CRM9 that can deplete in vivo T cells and induce long term tolerance of mismatched renal allograft in rhesus monkeys. This immunotoxin is a monkey analogu...

Ni, J.; Ji, J.; Bai, X.; Lu, A.; Huang, R.; Wei, Y.; Wu, W., 2007: Construction and expression of anti-GD2/anti-CD16 single-chain bispecific antibody. This study sought to construct a recombinant vector that expresses anti-GD2/anti-CD16 bispecific single-chain antibody(sc-BsAb), and to assess its biological activities. The anti-GD2 gene and the anti-CD16 gene (NM3E2) were obtained using PCR ampl...

Wang, D.; Wu, G-jun.; Wang, H.; Yang, S-liang.; Wu, W-zhen.; Xu, T-zhao.; Tan, J-ming., 2003: Construction and expression of anti-CD3/anti-prostate-cancer bispecific single-chain antibody. To construct a recombinant vector that expresses anti-CD 3/anti-prostate-cancer bispecific single-chain antibody (BsAb), and study its biological activities and clinical significance. An anti-CD 3/anti-prostate-cancer BsAb was constructed by PCR a...

Zamboni, S.; Mallano, A.; Flego, M.; Ascione, A.; Dupuis, M.Luisa.; Gellini, M.; Barca, S.; Cianfriglia, M., 2008: Genetic construction, expression, and characterization of a single chain anti-CEA antibody fused to cytosine deaminase from yeast. We report the genetic construction and expression of a fusion protein between a single chain fragment variable (scFv) human antibody (E8) specific for CEA cell surface antigen and yeast cytosine deaminase (yCD). Sequences encoding for the scFvE8...

Goshorn, S.C.; Svensson, H.P.; Kerr, D.E.; Somerville, J.E.; Senter, P.D.; Fell, H.P., 1993: Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase. We report the genetic construction and expression of a fusion protein between an antibody single chain-linked variable domain fragment specific for human carcinomas and beta-lactamase II from Bacillus cereus. Sequences encoding the variable region...

Haisma, H.J.; Sernee, F.; Brakenhoff, R.H.; V.D.Meulen Muielman, I.; Pinedo, H.M.; Boven, E., 1996: Construction and characterization of a single chain human beta-glucuronidase-anti-CD20 antibody fusion protein for antibody-directed enzyme prodrug therapy. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 472

Haisma, H.J.; Sernee, M.F.; Hooijberg, E.; Brakenhoff, R.H.; vd Meulen-Muileman, I.H.; Pinedo, H.M.; Boven, E., 1998: Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy. The CD20 antigen is an attractive target for specific treatment of B-cell lymphoma. Antibody-directed enzyme prodrug therapy (ADEPT) aims at the specific activation of a nontoxic prodrug at the tumor site by an enzyme targeted by a tumor-specific...